Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930416 | 0.76 | PNMT (0.43) | LIMK1PDK1CFTR | |
| SCHEMBL19441931 | 0.73 | KCNH2 (0.35) | LIMK1PDK1 | |
| SCHEMBL22817550 | 0.72 | PRKDC (0.36) | PDK1 | |
| SCHEMBL14925534 | 0.72 | PRKDC (0.36) | PDK1CFTR | |
| SCHEMBL14205894 | 0.70 | — | — | |
| SCHEMBL32687001 | 0.66 | MAPK1 (0.41) | — | |
| SCHEMBL30130749 | 0.65 | PTGER4 (0.41) | — | |
| SCHEMBL16809691 | 0.64 | FBP1 (0.34) | PDK1 | |
| SCHEMBL5456315 | 0.64 | — | — | |
| SCHEMBL21067434 | 0.63 | RAB9A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | LIMK1 3271/4885PDK1 353/4885CFTR 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.